This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D43 (Neoplasm of uncertain or unknown behavior of brain and central nervous system) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date) |
| B. Synonyms | Brain tumor of uncertain behavior, low-grade glioma, dysembryoplastic neuroepithelial tumor (DNET), pilocytic astrocytoma (D43.0/D43.1), spinal myxopapillary ependymoma |
| C. Adult onset | IDH-mutant low-grade glioma is common in the 20s~40s and often first presents with seizures. Pediatric-type low-grade glioma can also occur into early adulthood. |
| 1. History | Beginning with the glioma classification of Bailey and Cushing (1926), it shifted in the 2021 WHO classification to a molecularly based classification using IDH mutation, TERT, 1p19q, and others. |
| 2. Causes | Cranial irradiation is the main environmental risk factor, and hereditary syndromes (NF1, NF2, Li-Fraumeni, Turcot) are associated with onset in a minority. |
| 3. Genetics | IDH1/2 mutations (about 80% of adult-type low-grade gliomas), 1p19q codeletion (oligodendroglioma), and BRAF V600E/KIAA1549::BRAF fusion (pediatric-type, low grade) are the key molecular alterations. |
| 4. General epidemiology | Low-grade brain tumors account for about 30~35% of all primary brain tumors; IDH-mutant adult-type low-grade glioma is common in the 20s~50s. |
| 5. Pathophysiology | Overproduction of 2-HG (2-hydroxyglutarate) due to IDH mutation reprograms the epigenome, causing the CpG island methylator phenotype (CIMP). |
| 6. Symptoms | Seizures are the most common initial symptom (60~80%); headache, cognitive decline, and focal neurologic deficits may accompany them. |
| 7. Signs | Postictal Todd's paralysis, focal neurologic deficits (hemiparesis, aphasia, visual field defects, etc.), and signs of increased intracranial pressure (papilledema) may be found. |
| 8. Screening | Regular MRI follow-up in patients with hereditary syndromes such as NF1; immediate brain MRI evaluation is essential for new-onset seizures in adults. |
| 9. Diagnosis | MRI (FLAIR, T2, DWI, MRS), neurosurgical biopsy, and IDH, ATRX, and 1p19q molecular testing are central to diagnosis according to the 2021 WHO classification. |
| 10. Treatment | Maximal safe resection followed by combined radiation and temozolomide chemotherapy; targeted therapies such as IDH inhibitors (ivosidenib, vorasidenib) are being introduced. |
| 11. Prognosis | Median survival of IDH-mutant astrocytoma 6~10 years; median survival of 1p19q-codeleted oligodendroglioma 12~14 years, markedly better than IDH wild-type. |
| 12. Prevention | Minimizing cranial irradiation; early diagnosis and regular follow-up of hereditary syndromes; reducing exposure to environmental carcinogens are secondary prevention strategies. |
| 13. References | The 2021 WHO Classification of Tumors of the Central Nervous System: a summary … and 9 other papers |
The history of classification of brain and central nervous system tumors can be said to begin with the landmark 1926 book "A Classification of the Tumors of the Glioma Group" by Percival Bailey and Harvey Cushing. They systematically classified gliomas by cell of origin from a histogenetic perspective, and this classification served as the standard of neuro-oncology for decades thereafter. Bailey and Cushing's classification was based purely on histologic criteria, but its limitations in predicting the clinical course of tumors were gradually recognized.
In 1949, Kernohan et al. proposed a system classifying gliomas into Grades 1~4 by degree of malignancy, a new approach emphasizing the association with clinical prognosis. The WHO subsequently revised the glioma classification repeatedly in 1979, 1993, 2000, and 2007. The 2016 WHO classification of CNS tumors achieved a paradigm shift by formally integrating molecular markers into the tumor classification system. IDH (isocitrate dehydrogenase) mutation and 1p/19q codeletion were introduced as essential diagnostic criteria for oligodendroglioma, and IDH mutation status was established as the key factor in classifying adult diffuse gliomas.
The 2021 WHO classification of CNS tumors (5th edition) further deepened the molecularly based classification, separating adult-type diffuse gliomas (IDH-mutant astrocytoma, IDH-mutant oligodendroglioma, IDH wild-type glioblastoma) and classifying pediatric-type low-grade gliomas separately. TERT promoter mutation, EGFR amplification, and chromosome 7 gain + chromosome 10 loss were added as molecular diagnostic criteria for IDH wild-type glioblastoma. Brain and CNS tumors of "uncertain behavior" corresponding to the D43 code include WHO grade 1~2 gliomas, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor (DNET), myxopapillary ependymoma, ganglioglioma, and others.
Important Korean contributions to the history of brain tumor research include epidemiologic and clinical studies by institutions including the National Cancer Center, and the Korean Brain Tumor Society (KSBNS) plays a leading role in developing domestic practice guidelines. In Korea Central Cancer Registry data, brain and CNS tumors account for about 1.5~2% of all cancers, and their incidence is continuing to rise.
The causes of D43 neoplasms of uncertain behavior of the brain and CNS are mostly unknown, but some environmental factors and genetic predispositions have been identified. Cranial irradiation is the only definitively proven environmental risk factor for brain glioma. When high-dose radiation is given to the head in childhood (e.g., cranial treatment for leukemia, treatment of pediatric medulloblastoma), the risk of glioma and meningioma increases significantly decades later. Radiation-induced gliomas arise after a latency period of 10~20 years after irradiation and are often high grade.
Hereditary syndromes are associated with some low-grade brain tumors. Neurofibromatosis type 1 (NF1) is the most common risk factor for optic pathway glioma; optic pathway glioma develops in about 15~20% of NF1 patients and is mostly pilocytic astrocytoma. Li-Fraumeni syndrome (germline TP53 mutation) is associated with the development of pediatric high-grade glioma. Turcot syndrome is divided into an APC mutation form (glioblastoma) and an MLH1/MSH2 mutation form (medulloblastoma). Lynch syndrome (MMR gene mutations) is also partly associated with brain glioma risk.
Mobile phone electromagnetic waves, living near high-voltage power lines, and exposure to certain chemicals (formaldehyde, vinyl chloride, acrylonitrile) have been studied for association with brain glioma, but most large epidemiologic studies have not demonstrated a consistent association. Some studies have reported a paradoxical association in which allergic diseases (atopy, asthma) lower the risk of brain glioma, but the causal relationship is unclear.
In the 2021 WHO classification of CNS tumors, the molecular features of brain tumors corresponding to D43 were established as key classification criteria. IDH1/IDH2 mutations are the most important molecular markers of adult-type diffuse low-grade gliomas (WHO grade 2~3 astrocytoma, oligodendroglioma). The IDH1 R132H mutation accounts for about 90% of all IDH mutations, and IDH2 R172 mutations are found in about 5~10%. IDH mutations are found in about 80% of adult-type diffuse gliomas and serve as a favorable prognostic marker.
1p/19q codeletion, together with IDH mutation, is an essential diagnostic criterion for oligodendroglioma. This abnormality is the simultaneous loss of 1p and 19q due to an unbalanced translocation between chromosomes 1 and 19; it is associated with excellent sensitivity to temozolomide and PCV chemotherapy and is also used as a marker predicting response to chemotherapy. In IDH-mutant astrocytoma, ATRX mutation and TP53 mutation are characteristically found instead of 1p19q codeletion.
In pediatric-type low-grade gliomas, KIAA1549::BRAF gene fusion is found in about 60~80% of pilocytic astrocytomas, and the BRAF V600E point mutation is observed in about 15~20%. FGFR1 alterations and NTRK fusions are also important molecular abnormalities in pediatric-type low-grade gliomas and provide the basis for developing targeted therapies. FGFR1 alterations are characteristic of dysembryoplastic neuroepithelial tumor (DNET), and BRAF V600E of ganglioglioma.
Neoplasms of uncertain behavior of the brain and CNS corresponding to the D43 code account for a substantial part of all primary brain tumors. According to US CBTRUS data, low-grade (WHO grade 1~2) gliomas account for about 30~35% of all primary brain tumors. Pilocytic astrocytoma is the most common brain tumor in children, accounting for about 15~20% of all pediatric brain tumors, and most often arises in the cerebellum. The annual incidence of IDH-mutant adult-type low-grade glioma is about 0.5~1 per 100,000, and it is common in the 20s~50s.
Oligodendroglioma accounts for about 20~25% of all diffuse gliomas and occurs mainly in the frontal lobe of the cerebral hemispheres. IDH-mutant astrocytoma commonly occurs in the temporal, frontal, and parietal lobes, with a median age at onset of about 35~40. Ependymoma accounts for about 3~5% of all gliomas, and spinal ependymoma is more common in adults. Myxopapillary ependymoma (D43.4) is a special subtype arising in the conus medullaris/filum terminale of the spinal cord and is the most common spinal cord tumor in adults.
The best-characterized pathogenic mechanism in D43 brain tumors is epigenomic reprogramming due to IDH mutation. Gain-of-function mutations occurring at active-site arginine residues of IDH1 (cytoplasmic) or IDH2 (mitochondrial) produce the toxic metabolite 2-hydroxyglutarate (2-HG) instead of converting the normal substrate isocitrate to alpha-ketoglutarate (α-KG). 2-HG competitively inhibits α-KG-dependent dioxygenases (TET2, histone demethylases), inducing hypermethylation of CpG islands. This state is called the CpG island methylator phenotype (CIMP), and transcriptional silencing through promoter methylation of tumor suppressor genes is the key mechanism of carcinogenesis.
The KIAA1549::BRAF gene fusion in pilocytic astrocytoma constitutively activates BRAF kinase, persistently activating the MAPK (MEK-ERK) signaling pathway. Activation of this pathway promotes cell proliferation but at the same time also activates a tumor growth-suppressing mechanism that induces cellular senescence (oncogene-induced senescence), providing the biological basis for the self-limited growth pattern of the tumor. In BRAF V600E-mutant tumors, the cellular senescence mechanism is relatively weakened, allowing the potential for more aggressive growth. The mechanism by which 1p19q codeletion in oligodendroglioma promotes cell proliferation through loss of function of the CIC and FUBP1 genes (19q13 and 1p31, respectively) has also been studied.
The symptoms of D43 neoplasms vary with tumor location, size, growth rate, and relationship to surrounding brain structures. In adult IDH-mutant low-grade glioma, the most characteristic and common initial symptom is seizures, occurring in about 60~80% of all patients. Seizures may take various forms such as simple partial seizures, complex partial seizures, and generalized tonic-clonic seizures, and a first new-onset seizure in an adult is a strong indication for brain MRI evaluation. The seizure rate is particularly high in low-grade gliomas located in the frontal or temporal lobe.
Headache is the second most common symptom; initially it is hard to distinguish from nonspecific tension headache, but it may gradually progress to a pattern of increased intracranial pressure that worsens in the morning and is accompanied by nausea. Focal neurologic deficits reflect cortical dysfunction according to tumor location. Frontal lobe tumors cause aphasia (Broca or anomic aphasia), executive dysfunction, and personality change, and tumors adjacent to the motor cortex cause hemiparesis. Tumors adjacent to the visual cortex or optic radiation may cause homonymous hemianopia. In pediatric pilocytic astrocytoma, depending on location, cerebellar ataxia (cerebellum), hydrocephalus (obstruction of the 3rd~4th ventricles), and decreased vision (optic pathway glioma) appear.
The signs found on neurologic examination vary greatly with tumor location. Todd's paralysis immediately after a seizure is a transient focal motor paralysis that may commonly be observed in association with seizures due to low-grade glioma. With increased intracranial pressure, papilledema is found on funduscopy. In frontal lobe tumors, personality and behavioral changes, executive dysfunction, and decreased verbal fluency are identified on interview and neuropsychological testing.
In tumors adjacent to the motor cortex, hemiparesis (upper or lower limb predominant), upper limb drift (unilateral downward drift on arm extension testing), constructional apraxia, and hemisensory disturbance are observed. Tumors of the dominant hemisphere temporoparietal region cause aphasia (impaired language comprehension or expression), acalculia, and right-left confusion. Occipital lobe tumors cause homonymous hemianopia. Cerebellar pilocytic astrocytoma causes ipsilateral ataxia (dysmetria), dysdiadochokinesia, lateral nystagmus, and gait ataxia. Spinal myxopapillary ependymoma causes lower limb weakness, sensory disturbance, and bladder and bowel dysfunction.
Screening of the general population for neoplasms of uncertain behavior of the brain and CNS is not currently recommended. However, targeted surveillance in high-risk populations is important. In patients with NF1 syndrome, especially children, regular ophthalmologic examination (surveillance for optic pathway glioma) and brain MRI are recommended. In children with NF1, a baseline MRI is performed at diagnosis even without symptoms, with follow-up thereafter according to symptoms. Because about 50% of patients with optic pathway glioma are associated with NF1, NF1 genetic testing is recommended in patients newly diagnosed with optic pathway glioma.
In patients with Li-Fraumeni syndrome, multi-organ surveillance including brain MRI is performed as part of a whole-body cancer surveillance protocol (Toronto protocol). Brain MRI follow-up is also needed in patients diagnosed with Turcot syndrome. In adults with new-onset seizures, a change in the character of persistent headache, unexplained focal neurologic deficits, or cognitive decline, immediate brain MRI evaluation (with contrast enhancement if possible) is performed. Regular MRI follow-up is recommended in pediatric survivors who received brain radiation therapy to monitor for secondary brain neoplasms.
Diagnosis of D43 brain and CNS neoplasms is made by integrating MRI imaging with histopathologic and molecular pathologic testing. MRI is the key imaging tool for evaluating brain tumors. IDH-mutant low-grade gliomas appear on T2/FLAIR images as homogeneous, relatively well-defined hyperintense lesions, often with no or minimal contrast enhancement (the presence of enhancement suggests possible transformation to high grade). On diffusion-weighted imaging (DWI), ADC values are high, reflecting low cellular density, in contrast to the low ADC values of high-grade gliomas. On MR spectroscopy (MRS), increased choline, decreased N-acetylaspartate, and a 2-HG peak (specific to IDH-mutant tumors) may be observed.
Histologic and molecular pathologic diagnosis is currently made as an integrated diagnosis combining histologic type and molecular markers according to the 2021 WHO CNS classification. IDH1/2 mutations are first screened by immunohistochemistry (IDH1 R132H monoclonal antibody), and if negative, IDH2 and other IDH mutations are confirmed by Sanger sequencing or next-generation sequencing (NGS). 1p19q codeletion is confirmed by FISH or SNP array. ATRX, TP53, TERT promoter mutations, EGFR amplification, and 7+/10- chromosomal alterations are additionally used to determine WHO grade and subtype. DNA methylation profiling (Heidelberg Brain Tumor Classifier) is used as an adjunct in some cases of uncertain diagnosis.
Treatment of D43 brain and CNS neoplasms is individualized according to histologic type, location, molecular subtype, patient age, and functional status. Maximal safe resection contributes to improved survival and symptom relief in IDH-mutant low-grade glioma and is recommended as the standard first-line treatment. For tumors adjacent to functionally critical cortical areas, awake craniotomy and cortical mapping are used to pursue both functional preservation and maximal tumor resection. Fluorescence-guided surgery (5-ALA fluorescence) is used to increase the extent of resection in high-grade tumors.
Postoperative radiation therapy is applied to high-grade or incompletely resected low-grade gliomas. In IDH-mutant astrocytoma (WHO grade 2~3) and oligodendroglioma, the RTOG 9802 trial (long-term follow-up results) confirmed that radiation therapy combined with PCV (procarbazine + CCNU + vincristine) chemotherapy yields better survival than radiation alone. Temozolomide (TMZ) is also widely used. Recently, IDH inhibitors have emerged as a new target for treating IDH-mutant gliomas. The INDIGO trial (published in 2023) demonstrated that vorasidenib (a brain-penetrant dual IDH1/2 inhibitor) significantly improves progression-free survival in noninvasive IDH-mutant glioma. Dabrafenib + trametinib combination for BRAF V600E-mutant tumors, larotrectinib for NTRK fusion tumors, and FGFR inhibitors are in clinical trials for pediatric low-grade glioma.
The prognosis of D43 brain and CNS neoplasms is determined by IDH mutation status, presence of 1p19q codeletion, WHO grade, and extent of resection. IDH-mutant oligodendroglioma (1p19q-codeleted, WHO grade 2) has the most favorable prognosis, with a median survival of 14 years or more, and even at WHO grade 3 the median survival is 10~12 years. Median survival of IDH-mutant astrocytoma (WHO grade 2) is about 8~10 years, and of WHO grade 3 about 5~7 years.
Pediatric pilocytic astrocytoma is a WHO grade 1 tumor; with complete resection the 10-year survival rate exceeds 90%, and in some cases the prognosis approaches cure. Myxopapillary ependymoma also allows long-term survival with complete resection, but the prognosis worsens with spinal dissemination. IDH wild-type diffuse glioma falls under C71 (malignant) rather than the D43 category, but tumors classified as IDH wild-type on initial biopsy may progress to glioblastoma during follow-up. Poor prognostic factors include older age, low performance status (KPS), IDH wild-type, presence of contrast enhancement (possible high-grade transformation), and accompanying TERT mutation.
Primary prevention of brain and CNS neoplasms centers on minimizing cranial irradiation, the known risk factor. In treating pediatric brain tumors and head and neck cancers, the use of precision radiation techniques such as proton therapy, IMRT (intensity-modulated radiation therapy), and fractionated radiation therapy reduces unnecessary radiation exposure of normal brain tissue and lowers the risk of secondary glioma. Recognizing the risk of secondary brain tumors in pediatric survivors who received radiation therapy and conducting regular follow-up are important for early detection.
Genetic counseling and early diagnosis of hereditary syndromes (NF1, NF2, Li-Fraumeni, Turcot) enable early detection and appropriate follow-up within high-risk families. Regular ophthalmologic and neurologic evaluation is recommended in the children of NF1 patients for early detection of optic pathway glioma. At present, there is no strong evidence that any particular change in diet, lifestyle, or environmental exposure definitely lowers the incidence of brain tumors. Minimizing exposure to environmental carcinogens (especially industrial chemicals) and regular health checkups are recommended as general health prevention. The possibility of chemoprevention with IDH inhibitors has been suggested in the past, but it has not yet reached clinical application.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. DOI: 10.1093/neuonc/noab106. PMID: 34185076.
Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744. DOI: 10.1038/nature08617. PMID: 19935646.
Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343. DOI: 10.1200/JCO.2012.43.2674. PMID: 23249208.
Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344-1355. DOI: 10.1056/NEJMoa1500925. PMID: 27050206.
Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715. DOI: 10.1016/S1470-2045(12)70164-X. PMID: 22578793.
Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012;70(1):234-243. DOI: 10.1227/NEU.0b013e318223f5b4. PMID: 21792084.
Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398-3406. DOI: 10.1200/JCO.19.03327. PMID: 32530763.
Bodhinayake I, Symons M, Bhatt DL, et al. BRAF and MEK inhibition in gliomas with BRAFV600E mutation: a review. Front Oncol. 2023;13:1133726. DOI: 10.3389/fonc.2023.1133726. PMID: 37051545.
Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report 2014-2018. Neuro Oncol. 2021;23(Suppl 2):iii1-iii105. DOI: 10.1093/neuonc/noab200. PMID: 34608945.
Sturm D, Pfister SM, Jones DTW. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. J Clin Oncol. 2017;35(21):2370-2377. DOI: 10.1200/JCO.2017.73.0242. PMID: 28640699.